Patients with multiple sclerosis on long-term injectable therapies may suffer from the so-called "needle fatigue", i.e., a waning commitment to continue with the prescribed injectable treatment. Therefore, alternative treatment strategies to enhance patients' adherence are warranted. In this independent, multicentre post-marketing study, we sought to directly compare switching to either teriflunomide (TFN), dimethyl fumarate (DMF), or pegylated interferon (PEG) on treatment persistence and time to first relapse over a 12-month follow-up. We analyzed a total of 621 patients who were free of relapses and gadolinium-enhancing lesions in the year prior to switching to DMF (n = 265), TFN (n = 160), or PEG (n = 196). Time to discontinuation and time to first relapse were explored in the whole population by Cox regression models adjusted for baseline variables and after a 1:1:1 ratio propensity score (PS)-based matching procedure. Treatment discontinuation was more frequent after switching to PEG (28.6%) than DMF (14.7%; hazard ratio [HR] = 0.25, p < 0.001) and TFN (16.9%; HR = 0.27, p < 0.001). We found similar results even in the re-sampled cohort of 222 patients (74 per group) derived by the PS-based matching procedure. The highest discontinuation rate observed in PEG recipient was mainly due to poor tolerability (p = 0.005) and pregnancy planning (p = 0.04). The low number of patients who relapsed over the 12-month follow-up (25 out of 621, approximately 4%) prevented any analysis on the short-term risk of relapse. This real-world study suggests that oral drugs are a better switching option than low-frequency interferon for promoting the short-term treatment persistence in stable patients who do not tolerate injectable drugs.
Background
Multiple sclerosis (MS) is a life-long disease that requires long-lasting treatment to prevent relapses and disability accumulation [1] . Treatment adherence represents a key component in the disease management that includes acceptance, persistence, and compliance to prescribed therapy [2, 3] . Moreover, even if there is robust evidence on the benefits of disease-modifying treatments (DMTs), their effectiveness at individual level is difficult to perceive on an immediate basis. Therefore, while a number of patients discontinue treatment in the first treatment year (17-46%) mainly due to intolerable side effects [4, 5] , there are equally important groups of patients who discontinue many years later (30-40%) or who are not adherent to treatment in terms of both recommended dose and timing administration [6] [7] [8] [9] [10] . In any case, poor adherence to DMTs has been associated with increases in MS-related hospitalizations and relapse rates [11, 12] .
Patients on long-term injectable therapies, especially high-frequency interferon beta (IFNB) and glatiramer acetate (GA), may suffer from the so-called "needle fatigue" [13] , i.e., a waning commitment to continue with the prescribed injectable treatment, that results in loss of adherence due to difficulties with injections, anxiety/depression, or inaccurate beliefs about the MS disease process [5] [6] [7] [8] .
Patients may self-reduce the administration frequency of injective treatments, especially IFNB, to avoid unpleasant side effects or for forgetfulness. To date, the long-term consequences on disease activity of reducing administration frequency of high-frequency IFNB are still only partially known and few post-marketing observational studies provided discouraging results due to re-start of disease activity following IFNB dose reduction [14, 15] . Longer persistence to treatment has been instead reported with GA [16] and the introduction of three times weekly GA 40 mg has also offered a relatively more tolerable administration regimen for patients with poor needle tolerance [17] .
Given the increasing availability of oral drugs for MS, namely once daily teriflunomide (TFN) and twice daily dimethyl fumarate (DMF), a potential strategy to enhance adherence in the long term might be switching from an injective to an orally administered treatment [18] [19] [20] . Another potential strategy encompasses the reduction of IFNB administration frequency by switching to pegylated interferon (PEG) that is given every 2 weeks.
Here, we sought to directly compare switching to either TFN, DMF, or PEG on treatment persistence and time to first relapse over a 12-month follow-up in patients who complained of needle fatigue while on high-frequency IFNB or GA.
Methods

Study design and participants
This was an independent, multicentre, post-marketing study. We retrospectively analyzed data of patients affected by relapsing-remitting MS who regularly attended ten outpatient MS Clinics in Central Italy. Monitoring and management of patients with MS on DMTs are highly homogeneous in Central Italy as a result of a consensus statement reached by stakeholders, including local health authorities, clinicians, health care professionals, patients, and health foundations [21] .
In April 2018, clinicians from each participating MS Clinics convened to a workshop in Rome where an 'ad hoc' shared electronic spreadsheet was created to collect clinical data for analyses. Collected data were centrally reviewed for discrepancies by the two lead authors who sent queries (if necessary) to reach data harmonization. The final data analysis was performed in February 2019.
We considered data of patients who complained of lack of tolerance to self-injectable high-frequency IFNB or GA and were, therefore, switched to either TFN, DMF, or PEG. Included patients had the following characteristics at the time of treatment switch (henceforth defined as 'baseline'): (i) age from 18 to 65 years (inclusive); (ii) diagnosis of relapsing-remitting MS according to the Mc Donald revised criteria [22] ; (iii) Expanded Disability Status Scale (EDSS) [23] score from 0 to 5.5 (inclusive); (iv) freedom from relapses and from magnetic resonance imaging (MRI) activity-seen as gadolinium-enhancing lesions-in the year prior to switching treatment to either TFN, DMF, or PEG.
This study was conducted in accordance with specific national laws and the ethics standards laid down in the 1964 Declaration of Helsinki and its later amendments. In no way this study did interfere in the care received by patients.
Anonymized data presented in this article will be made available at the request of a qualified investigator; requests should be sent to Dr. Prosperini (luca.prosperini@gmail. com).
Outcome measures
All outcomes were investigated over a time window of 12 months after the baseline visit.
As the primary outcome, we estimated treatment persistence, i.e., the time to treatment discontinuation over a 12-month follow-up period.
In addition, we also collected reasons for discontinuation that were categorized into four groups as follows:
(1) disease activity, i.e., radiological and/or clinical events that led neurologists to discontinue treatment for lack of efficacy; (2) poor tolerability, i.e., when discontinuation was 'patient-driven' due to expected side effects; (3) adverse events, i.e., when discontinuation was 'physician-driven' due to medical concern for expected or unexpected side effects; (4) others, i.e., any reason not included in the previous definitions (e.g. pregnancy desire, patient's decision, etc.).
As the secondary outcome, we estimated the proportion of patients who relapsed over the 12-month follow-up period. A relapse was defined as any new neurologic symptom not associated with fever or infection lasting for at least 24 h and accompanied by new neurologic signs [22] .
Statistical analysis
Data are presented as count (proportion) for categorical variables and mean (standard deviation) (SD) or median [interval] for continuous variables. We considered the following data at baseline: sex, age, time since first symptom, EDSS score, and prior treatment (IFNB or GA). Baseline variables were tested for differences across post-switch treatment groups (TFN, DMF, and PEG) by the Chi-squared test (for categorical variables) and the Kruskal-Wallis test (for continuous variables).
Primary and secondary outcomes were formerly explored in the whole sample by Kaplan-Meier survival curves and Cox proportional hazard regression models stratified by site and adjusted for the aforementioned baseline variables.
Successively, since patients were not randomized to treatment group, we also conducted a 1:1:1 ratio propensity score (PS)-based nearest neighbor matching within a caliper of 0.05 (without replacement), with exact match by sex and prior treatment [24] . We derived then two separate PS values estimating the conditional probability to receive DMF versus PEG and TFN versus PEG, respectively. Matched pairs of subjects with overlapping PS values in DMF and TFN groups were compared according to the common-referent approach procedure [25] . The validity of PS matching was tested by analysis of standardized differences (|d|), with |d| > 0.20 considered as imbalance [26] . Primary and secondary outcomes were then explored in matched samples by Kaplan-Meier survival curves and Cox proportional hazard regression models, adjusted for sex and age at baseline, and stratified by matched cases [27] . As main time variable, we used the length of the observation (in months) from the baseline visit to outcome reach; otherwise, the follow-up period was right-censored at 12 months in patients who did not reach the outcome. Postestimation sensitivity analyses were applied to test the sensitivity of the matched models to a hypothetical confounder that was either not collected or incompletely observed [28] .
Graphic inspection of log-minus-log survival plots confirmed the proportional hazard assumption in the whole sample and in post-matching analyses. Linear dependence among covariates was assessed by collinearity diagnostic that showed no evident collinearity, being the variance inflation factors < 1.6 for all variables (see the supplemental data).
Reasons for discontinuation were analyzed separately by the Chi-squared test.
Two-tailed p values < 0.05 were considered as significant. Analyses were carried out using a PC version of Statistical Package for Social Sciences 16.0 (IBM SPSS, Chicago, Illinois).
Results
Participants
From an original cohort of 1866 patients starting PEG, DMF, or TFN from 2013 to 2018, we collected data from 621 patients who were switched from either IFNB (n = 434) or GA (n = 187) to either TFN (n = 160), DMF (n = 265), or PEG (n = 196). Their baseline characteristics before and after the PS-based matching procedure are shown in Table 1 . Patients who were switched to TFN were older, had longer time since first MS symptom, and higher EDSS score than patients switched to both DMF and PEG (p < 0.05). Patients who discontinued GA were more likely to be switched to DMF than to TFN or PEG (p < 0.05).
This between-group imbalance did not persist after the matching procedure that retained 222 patients (74 per group; see also Fig. 1 ) No covariate exhibited large imbalance (|d| < 0.20) in the re-sampled population (Fig. 2) .
Findings on the whole sample
The proportions of patients who discontinued treatment were 16.9%, 14.7%, and 28.6% after switching to TFN, DMF, and PEG, respectively.
Reasons for treatment discontinuation after switching are shown in Table 2 . The side effects reported by patients were consistent with each drug's profile (flu-like syndrome and leukopenia for PEG; flushing, gastrointestinal disturbances, and lymphopenia for DMF; hair thinning, high blood pressure values, and liver enzyme increase for TFN). No serious adverse event was reported. Other reasons for discontinuation were pregnancy desire or planning (n = 8) and patient's refuse to continue any type of treatment (n = 11). Rates of discontinuation due to disease activity and adverse events were similar across treatment groups. PEG was discontinued more often due to poor tolerability (p = 0.005) and other reasons, especially pregnancy desire or planning (p = 0.04), when compared with both DMF and TFN.
According to the Cox model conducted in the whole sample (Table 3 and Fig. 3a ), the risk of treatment discontinuation was reduced after switching to both DMF (HR = 0.25) and TFN (HR = 0.27) when compared to PEG (p values < 0.001). There was no difference between DMF and TFN (p = 0.54). We found no significant difference across PEG, DMF, and TFN in terms of post-switch relapses (see also Table 3) ; probably, the overall very low number of events (n = 25, 4%) did not allow to find statistically significant between-group difference. The median time from baseline to first relapse was 8 months (interval: [4] [5] [6] [7] [8] [9] [10] [11] [12] ; most relapses (20/25, 80%) occurred > 6 months from baseline.
Findings on the re-sampled population
After the PS-matching procedure, we analyzed 74 patients per group with similar baseline characteristics. Across them, the proportions of patients who discontinued treatment were 17.6%, 21.6%, and 36.5% after switching to TFN, DMF, and PEG, respectively. This finding suggests that the re-sampling procedure selected a subgroup of patients at higher risk of treatment discontinuation, regardless of the switch strategy adopted.
The Cox model on the re-sampled population showed that the risk of treatment discontinuation was reduced after switching to both DMF (HR = 0.56) and TFN (HR = 0.46) when compared with PEG. However, only the comparison between TFN and PEG reached the customary level of statistical significance (p = 0.03), whereas the comparison between DMF and PEG did not (p = 0.10) (Fig. 3b ). We found no significant difference between DMF and TFN (HR = 1.02; p = 0.92).
Overall, only 9 patients (4%) relapsed over the 12-month follow-up, 1 switched to PEG, 2 switched to DMF, and 6 switched to TFN (p = 0.12). As occurred in the overall study population, the small number of events in the re-sampled cohort prevented to find any statistically significant difference across treatment groups for the relapse outcome.
The sensitivity analysis was conducted only on the primary outcome (treatment discontinuation) and was restricted to the comparison between TFN and PEG, given the not significant difference between PEG and DMF, and the impossibility to perform any further statistical inference on the secondary outcome (relapses) due to the small number of events. We found that the relative risk estimate of a hypothetical unmeasured binary confounder should be at least 1.40 to alter the significant difference in the proportions of patients discontinuing treatment between PEG and TFN.
Discussion
In this multicenter, retrospective, real-world study, we provide a direct comparisons of three different treatments, namely TFN, DMF, and PEG, prescribed after suspension of high-frequency IFNB or GA due to needle fatigue. We selected a specific population of patients with MS, with a mean age above 40 years, a relatively long-term disease history, and no evidence of disease activity in the last year, as they could be considered 'treatment responders' who had most to lose from discontinuing injective treatments or reducing the administration frequency of IFNB or GA [4, 8, 14, 15] . A large long-term, cohort study conducted at the Calgary MS Clinic showed that, among patients who discontinued injective treatments (41% out of 1471 included in the survival analysis) after a median time of 11 years, almost a half remained off treatment [16] : the main reason for discontinuing injective treatments was intolerance (48%), more often reported by patients treated with IFNB than with GA [16] .
We found that, in this specific context, oral drugs were the best switching option for promoting short-term treatment persistence and lower proportion of treatment discontinuation (primary outcome of the present study). Two different statistical methods (Cox regression models adjusted for baseline covariates on the whole population and after PS-score based re-sampling) led to similar results, thus enhancing the robustness of our findings. We postulate that the oral route of administration promotes patient satisfaction and increases therapeutic compliance, despite greater safety and tolerability concerns about oral drugs mainly due to shorter experience in clinical practice [29] . A recent cross-sectional study conducted in Spain showed that the patients' level of satisfaction was higher with oral treatments; however, oral administration showed also a greater lack of adherence, mainly due to forgetfulness [30] .
In our study, reasons for treatment discontinuation after switching from high-frequency IFNB and GA were quite similar across treatments, except for PEG which was discontinued more often for poor tolerability than TFN and DMF. Switching to PEG would theoretically be an interesting alternative for patients who prefer less frequent injections [31] . However, its poor tolerability profile (flu-like syndrome, skin reactions) does not always make the switch successful [18] .
Our findings are in line with previous studies reporting a similar discontinuation rate for TFN and DMF [32] [33] [34] [35] , but conflict with a recently published large post-marketing analysis conducted in France showing a higher rate of treatment discontinuation in TFN-treated patients due to lack of effectiveness, especially for MRI activity [36] . This discrepancy might be explained not only by longer follow-up (2 years) of the French study, but also by different characteristics of the two study populations. In the French sample, more than 1700 patients were enrolled likely because of the less stringent inclusion criteria [36] .
The low number of relapses occurred over the 12-month follow-up in our sample (~ 4%) prevented any analysis on the short-term risk of relapse (secondary outcome of the present study) in both unmatched and the matched cohorts. This is quite expected, since the eligibility criteria (excluding patients with recent relapses and MRI activity) selected patients with a very mild disease activity.
Additionally, our data are in line with other Italian realworld experiences, where TFN were prescribed mainly to older male patients, while DMF and PEG were prescribed mainly to younger women, probably reflecting concerns about the TFN-related pregnancy risk and the possibility of hair thinning [18, 33, 34] .
The present study is not exempt from limitations, mainly due to its small sample size, lack of blindness and randomization, and the reliance on retrospectively rather than prospectively collected data, thus introducing hidden and recall biases [37] . Even if clinical data were collected by a spontaneous network after reaching an agreement on the minimum dataset to be analyzed, we cannot still exclude a certain degree of between-center variability. Moreover, we cannot provide MRI data over the 12-month follow-up period, thus failing to explore if the tree different treatment strategies after switching therapy might have had an effect on the development of gadolinium-enhancing lesions and/or new T2-hyperintense lesions. Another potential source of bias is the lack of information on the number of prior treatments, as it has been hypothesized that there is a subgroup of patients who are more likely to suspend multiple treatments due to poor tolerability [18] .
From a statistical point of view, we should also consider that PS matching is prone to the so-called ''bias due to incomplete matching'', and this may raise some concerns about the generalizability of our results [38] . However, given that the former analyses (based on Cox regression models running on data of the whole population and adjusted by all the available baseline variables) provided results consistent with the PS-matched analyses, we consider it a negligible bias [39, 40] .
In conclusion, our study suggests that switching to an oral drug such as either TFN or DMF might be a successful treatment strategy in case of needle fatigue. Being an observational, post-marketing report based on retrospectively collected data, this should be cautiously interpreted and considered only as 'hypothesis-generating'. Further efforts are warranted now to replicate our findings in larger sample sizes.
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